NYSE:ABBV
AbbVie Stock News
$166.42
+2.07 (+1.26%)
At Close: May 17, 2024
20 Years To $300k? Building A $10,000 Dividend Portfolio From Scratch
07:00am, Saturday, 20'th Apr 2024
Focusing on consistent dividend growth can lead to higher returns in lower-risk areas. The portfolio emphasizes companies with wide-moat business models, strong financials, and a commitment to shareho
Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
11:06am, Friday, 19'th Apr 2024
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
06:51pm, Wednesday, 17'th Apr 2024
AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.
Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now
02:56pm, Tuesday, 16'th Apr 2024
Blue-chip dividend stocks have always been relevant. While they're not the most exciting investments, they provide a steady hand during market uncertainty.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:05am, Tuesday, 16'th Apr 2024
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is AbbVie a Millionaire Maker?
01:23am, Sunday, 14'th Apr 2024
AbbVie has a handful of desirable features as an investment. It's also navigating a period of uncertainty successfully so far.
AbbVie: Bulletproof Fundamentals
02:10pm, Friday, 12'th Apr 2024
AbbVie is a profitability superstar with a strong track record of success, generating almost 40% in free cash flow margin. The company has a diverse portfolio of products across several promising drug
AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%
11:35am, Friday, 12'th Apr 2024
AbbVie's stock has outperformed the market over the past decade, with a 248.90% appreciation. Despite losing patent protection for Humira, which accounted for 37% of revenue in 2022, AbbVie remains un
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
06:51pm, Thursday, 11'th Apr 2024
The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
01:10pm, Thursday, 11'th Apr 2024
Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally.
Are You Looking for a High-Growth Dividend Stock?
12:46pm, Wednesday, 10'th Apr 2024
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
04:21am, Tuesday, 09'th Apr 2024
AbbVie's dividend payout has more than tripled over the past decade, and it could soar much further in the decade ahead. Bristol Myers Squibb offers a juicy 4.7% dividend yield at recent prices.
Here's Why AbbVie (ABBV) Fell More Than Broader Market
06:56pm, Monday, 08'th Apr 2024
In the latest trading session, AbbVie (ABBV) closed at $169.80, marking a -0.12% move from the previous day.
AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision
11:25am, Monday, 08'th Apr 2024
AbbVie's stock price fell by about 7% last week after the company revised its full-year and Q1 guidance downward.
Is Johnson & Johnson Stock A Better Pick Over AbbVie?
07:30am, Monday, 08'th Apr 2024
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer AbbVie (NYSE: ABBV). AbbVie ABBV trades at a higher valuation of 5.5x trailing rev
